About
Welcome to the Regional Summit on oHCM Management,
a premier gathering dedicated to advancing the understanding
and treatment of obstructive hypertrophic cardiomyopathy.
Taking place on 3-4 October 2025, at the Grand Hotel Union Eurostars in Ljubljana, Slovenia, this summit marks a significant milestone with the launch of mavacamten, novel therapy for oHCM.
Mavacamten is developed by MyoKardia, Inc., a Bristol Myers Squibb company, as a novel therapy for treatement of oHCM. Bristol Myers Squibb is company with 70 year legacy of discovering and developing paradigm-changing medicines, leveraging experience and expertise formed over the past several decades to take cardiovascular research to the next level.
This event brings together some of Europe’s leading experts in oHCM, uniting distinguished cardiologists, imaging specialists and clinicians to share cutting-edge insights and foster collaboration. The agenda is meticulously designed to address the latest advancements in oHCM management, from pathophysiology and precision diagnostics to clinical evidence and practical considerations for mavacamten therapy. Key sessions will cover diagnostic challenges, real-world evidence, multidisciplinary care, and patient-centered approaches, featuring keynote lectures, case studies, and interactive panel discussions led by renowned experts from across Europe.
We warmly welcome all attendees, whose high expertise and dedication to oHCM are pivotal to shaping the future of patient care. Your participation in this dynamic summit will contribute to transformative discussions, enhance clinical practice, and drive innovation in oHCM management. Join us for an inspiring two days of knowledge exchange, networking, and celebration of this landmark moment in cardiovascular medicine.
We look forward to your invaluable contributions and to welcoming you to Ljubljana!
Your Swixx Biopharma